查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2041818

停經後骨質疏鬆症治療市場預測至2034年－全球按治療方法、給藥途徑、藥物輸送系統、病患細分、分銷管道和地區分類的分析

Postmenopausal Osteoporosis Treatment Market Forecasts to 2034 - Global Analysis By Treatment Type, By Route of Administrations, By Drug Delivery System, Patient Demographics, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球停經後骨質疏鬆症治療市場規模將達到 98 億美元，並在預測期內以 6.6% 的複合年成長率成長，到 2034 年將達到 163 億美元。

停經後骨質疏鬆症的治療包括藥物治療和生活方式調整，旨在減輕停經後女性的骨質流失。常用治療方法包括雙磷酸鹽、荷爾蒙療法和單株抗體，這些藥物旨在增強骨骼並降低骨折風險。這些治療方法有助於維持骨骼密度、緩解症狀並改善整體骨骼健康。

根據世界衛生組織（世衛組織）2021年10月發布的報告，預計60歲以上人口將從2020年的10億增加到2030年的14億，到2050年將達到21億。國際更年期協會（IMS）發布的數據顯示，2021年有超過2億女性患有骨質疏鬆症，預計50歲及以上女性中每三人就有一人會因骨質疏鬆症而發生骨折。

全球老化進程

隨著進入晚期閉經的女性人數增加，骨質疏鬆症的盛行率也隨之上升，其特徵是骨骼密度下降和骨折風險增加。這種人口結構的改變促使研發部門加大力度，以滿足停經後女性的特定需求。製藥公司越來越專注於治療方法治療方法這一人群的治療方案，從創新藥物到標靶治療方法，加上醫療保健系統為應對老齡化社會中易患骨質疏鬆症相關併發症的需求而做出的努力，共同推動了市場成長。

高昂的醫療費用

骨質疏鬆症藥物和治療帶來的經濟負擔，對患者的普及和負擔能力構成了挑戰，尤其是在醫療資源有限或保險覆蓋不足的地區。骨質疏鬆症的治療費用通常不僅包括藥物，還包括診斷檢查、後續觀察和潛在副作用的管理，這進一步加重了患者的財務負擔。由於骨質疏鬆症是一種需要長期管理的慢性疾病，累積的經濟壓力可能會導致一些患者猶豫是否要尋求或繼續治療。

人們越來越意識到骨骼健康的重要性

隨著人們對骨質疏鬆症風險和後果的認知不斷提高，對預防和治療性介入的需求也日益成長。公眾宣傳宣傳活動和醫療保健舉措在鼓勵人們重視骨骼健康、及時篩檢和尋求適當治療方面發揮著至關重要的作用。這種意識的提高不僅促進了早期診斷，還提高了骨質疏鬆症治療的可及性，並創造了一個有利於患者積極管理自身骨骼健康、預防停經後骨質疏鬆症併發症相關併發症的市場環境。

與副作用和安全性相關的問題

儘管目前有多種藥物療法可以改善停經後女性的骨骼健康，但潛在的副作用會導致患者依從性下降，甚至中斷治療。除了常見的副作用，例如胃腸道問題和肌肉骨骼疼痛外，還可能出現非典型骨折和下顎骨壞死等嚴重併發症，這引起了患者和醫護人員的擔憂。這些安全問題不僅影響患者的生活品質，還會損害市場信譽和信任。

新冠疫情的影響：

新冠疫情對市場產生了重大影響。封鎖措施、醫療服務中斷以及資源被轉移用於對抗疫情，都為患者獲得診斷和治療帶來了挑戰。預約延期和患者數量減少影響了骨質疏鬆症的治療。此外，供應鏈中斷也影響了藥物的供應。然而，疫情加速了遠端醫療和數位健康解決方案的普及，為患者照護提供了新的途徑。對整個醫療系統韌性的日益重視以及對預防措施重要性的認知，可能會影響疫情後停經後骨質疏鬆症的治療策略。

在預測期內，荷爾蒙補充療法預計將佔據最大的市場佔有率。

荷爾蒙補充療法（ HRT）市場預計將迎來顯著成長。停經後女性雌激素水平下降會導致骨吸收增加，從而提高骨質疏鬆症的風險。 HRT透過補充雌激素（有時也包括黃體素）來減輕這些影響，促進骨骼密度維持和預防骨折。儘管其療效已得到證實，但由於心血管風險等相關風險，HRT的使用仍需謹慎評估。目前的研究重點在於最佳化HRT方案，以最大限度地發揮其益處，同時最大限度地減少其在治療停經後骨質疏鬆症方面的潛在弊端。

在預測期內，醫院藥房細分市場預計將呈現最高的複合年成長率。

在預測期內，醫院藥房領域預計將呈現最高的複合年成長率。醫院藥局確保處方藥物的可靠供應，提供病患教育，並促進醫護人員與接受停經後骨質疏鬆症治療的病患之間的順暢協作。憑藉其在藥物管理方面的專業知識，醫院藥房有助於提高患者的治療依從性，並為患者提供獲取必要治療方法（包括新興和創新治療方法）的中心樞紐。這項關鍵作用凸顯了醫院藥局在支持有效醫療服務和促進停經後骨質疏鬆症治療取得良好療效方面的重要作用。

市佔率最大的地區：

在預測期內，北美市場預計將繼續佔據市場主導地位，這主要得益於該地區人口老化程度高以及醫療保健基礎設施完善。該地區停經停經後骨質疏鬆症的盛行率很高，因此對有效治療方法的需求十分旺盛。技術進步、成熟的製藥公司以及有利的醫保報銷政策都促進了市場成長。此外，該地區正在進行的研究舉措和臨床試驗專注於創新治療方法，這使得北美成為開發和商業化新型停經後骨質疏鬆症治療方法的領先中心。

複合年成長率最高的地區：

預計亞太地區在預測期內將維持最高的複合年成長率，這主要得益於人們健康意識的不斷提高。尤其是在日本和中國等國家，人口老化加劇了骨質疏鬆症的盛行率，從而推動了對有效治療方法的需求。此外，人們健康意識的提高、醫療設施的改善以及政府為解決女性健康問題所採取的舉措，都進一步促進了市場擴張。同時，製藥公司與醫療機構的合作，以及治療方案的進步，正在推動亞太地區停經後骨質疏鬆症治療領域的創新，進而改善整體市場格局。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 應客戶要求，我們提供主要國家的市場估算和預測，以及複合年成長率（註：需進行可行性檢查）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

第2章：引言

  • 概括
  • 相關利益者
  • 調查範圍
  • 調查方法
  • 研究材料

第3章 市場趨勢分析

  • 促進因素
  • 抑制因子
  • 機會
  • 威脅
  • 新興市場
  • 新冠疫情的感染疾病

第4章：波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的競爭

第5章 全球停經後骨質疏鬆症治療市場：依治療類型分類

  • 雙磷酸鹽製劑
  • 荷爾蒙補充療法（HRT）
  • 選擇性雌激素受體調節（SERMs）
  • 單株抗體
  • 鈣和維生素D補充劑
  • 同化促效劑
  • 其他治療方法

第6章 全球停經後骨質疏鬆症治療市場：依給藥途徑分類

  • 口服
  • 腸外
    • 靜脈注射（IV）
    • 肌肉內部
    • 皮下
  • 經皮
  • 鼻腔

第7章 全球停經後骨質疏鬆症治療市場：依藥物輸送系統分類

  • 傳統配方
  • 長效配方

第8章 全球停經後骨質疏鬆症治療市場：依患者族群分類

  • 停經後婦女
  • 老年人口

第9章 全球停經後骨質疏鬆症治療市場：依分銷管道分類

  • 醫院藥房
  • 零售藥房
  • 網路藥房

第10章 全球停經後骨質疏鬆症治療市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太國家
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • UAE
    • 卡達
    • 南非
    • 其他中東和非洲國家

第11章 主要發展

  • 合約、夥伴關係、合作關係、合資企業
  • 收購與併購
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第12章：公司簡介

  • AbbVie Company（Allergan Pharmaceuticals International Ltd.）
  • Sun Pharmaceutical Industries Ltd.
  • Amgen Inc.
  • BiologicsMD
  • Chugai Pharma China Co., Ltd.（Roche）
  • Clonz Biotech
  • Proctor & Gamble Co.
  • Eli Lilly and Company
  • Enteris BioPharma
  • Ligand Pharmaceuticals Incorporated.
  • Pfizer Inc.
  • Merck Sharp & Dohme Corp.（Merck & Co., Inc.）
  • Mylan Inc.（Viatris）
  • Oncobiologics, Inc.
  • Novartis International AG
Product Code: SMRC24884

According to Stratistics MRC, the Global Postmenopausal Osteoporosis Treatment Market is accounted for $9.8 billion in 2026 and is expected to reach $16.3 billion by 2034 growing at a CAGR of 6.6% during the forecast period. Postmenopausal osteoporosis treatment involves medications and lifestyle modifications to mitigate bone loss in women after menopause. Common treatments include bisphosphonates, hormone therapy, and monoclonal antibodies, which aim to strengthen bones and reduce fracture risk. These treatments help maintain bone density, alleviate symptoms and enhance overall bone health.

According to the World Health Organization's October 2021 report, the population of people of age 60 years and more is expected to increase from 1 billion in 2020 to 1.4 billion by 2030 and 2.1 billion by 2050. According to data published by the International Menopause Society (IMS), in 2021, more than 200 million women are estimated to suffer from osteoporosis, and 1 in 3 women aged more than 50 is expected to experience osteoporosis fracture.

Market Dynamics:

Driver:

The increasing global aging population

With a rising number of individuals entering the postmenopausal phase, there is a subsequent increase in the prevalence of osteoporosis, a condition characterized by reduced bone density and increased fracture risk. This demographic shift creates a growing demand for effective treatment options to address the specific needs of postmenopausal women, fostering research and development initiatives. Pharmaceutical companies are increasingly focusing on developing therapies tailored to this demographic, ranging from innovative drugs to targeted interventions, driving market growth as healthcare systems strive to meet the evolving needs of an aging population susceptible to osteoporosis-related complications.

Restraint:

High treatment costs

The financial burden associated with osteoporosis medications and therapies poses challenges to widespread accessibility and affordability, particularly for patients in regions with limited healthcare resources or inadequate insurance coverage. The cost of osteoporosis treatment often includes not only medication expenses but also diagnostic procedures, monitoring tests, and potential side-effect management, further exacerbating the economic burden on patients. As osteoporosis is a chronic condition requiring long-term management, the cumulative financial impact can dissuade individuals from seeking or continuing treatment.

Opportunity:

Growing awareness regarding the importance of bone health

As awareness grows regarding the risks and consequences of osteoporosis, there is a heightened demand for preventive and therapeutic interventions. Public education campaigns and healthcare initiatives play a pivotal role in encouraging individuals to prioritize bone health, undergo timely screenings, and seek appropriate treatment. This heightened awareness not only fosters early diagnosis but also propels the adoption of osteoporosis treatments, creating a positive market environment where patients are more proactive in managing their bone health and preventing complications associated with postmenopausal osteoporosis.

Threat:

Adverse effects and safety issues

While various pharmaceutical interventions aim to address bone health in postmenopausal women, the potential for adverse reactions may lead to decreased patient compliance and treatment discontinuation. Common side effects such as gastrointestinal disturbances, musculoskeletal pain, and, in some cases, severe complications like atypical fractures or osteonecrosis of the jaw raise concerns among both patients and healthcare providers. These safety issues not only impact the quality of life for affected individuals but also undermine the market's credibility and trust.

Covid-19 Impact:

The COVID-19 pandemic has significantly impacted the market. Lockdowns, disrupted healthcare services, and diverted resources to combat the virus have led to challenges in patient diagnosis and treatment accessibility. Delayed medical appointments and reduced patient visits have affected osteoporosis management. Additionally, supply chain disruptions have impacted drug availability. However, the pandemic has accelerated the adoption of telemedicine and digital health solutions, offering alternative avenues for patient care. The focus on overall healthcare resilience and the importance of preventive measures may influence post-pandemic strategies in managing postmenopausal osteoporosis.

The hormone replacement therapy is expected to be the largest during the forecast period

The hormone replacement therapy segment is expected to have a lucrative growth. In postmenopausal women, reduced estrogen levels result in increased bone resorption, elevating the risk of osteoporosis. HRT involves the administration of estrogen and sometimes progestin to mitigate these effects, promoting bone density maintenance and fracture prevention. Despite proven efficacy, HRT usage is carefully evaluated due to associated risks, such as cardiovascular concerns. Ongoing research focuses on optimizing HRT protocols to maximize benefits while minimizing potential drawbacks in postmenopausal osteoporosis management.

The hospital pharmacies segment is expected to have the highest CAGR during the forecast period

The hospital pharmacies segment is anticipated to witness the fastest CAGR growth during the forecast period. They ensure the availability of prescribed treatments, provide patient education, and facilitate seamless coordination between healthcare professionals and individuals undergoing postmenopausal osteoporosis treatment. Hospital pharmacies contribute to treatment adherence through their expertise in medication management, offering a centralized hub for patients to obtain necessary medications, including emerging and innovative therapies. This integral role underscores their significance in supporting effective healthcare delivery and promoting positive outcomes in the management of postmenopausal osteoporosis.

Region with largest share:

During the forecast period, it is expected that the North American market will continue to hold a majority of the market driven by a substantial aging population and advanced healthcare infrastructure. The region benefits from a high prevalence of postmenopausal osteoporosis, necessitating a robust demand for effective treatments. Technological advancements, well-established pharmaceutical companies, and favorable reimbursement policies contribute to the market's growth. Moreover, ongoing research initiatives and clinical trials in the region focus on innovative therapies, positioning North America as a key hub for the development and commercialization of new and advanced treatments for postmenopausal osteoporosis.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period, driven by a growing health-conscious population. The increasing aging population, particularly in countries like Japan and China, contributes to a higher prevalence of osteoporosis, driving the demand for effective treatments. Rising healthcare awareness, improving access to medical facilities, and government initiatives to address women's health issues further propel market expansion. Additionally, collaborations between pharmaceutical companies and healthcare organizations, coupled with advancements in treatment options, are fostering innovation and enhancing the overall landscape for postmenopausal osteoporosis treatment in the Asia Pacific region.

Key players in the market

Some of the key players in Postmenopausal Osteoporosis Treatment market include AbbVie Company (Allergan Pharmaceuticals International Ltd.), Sun Pharmaceutical Industries Ltd., Amgen Inc., BiologicsMD, Chugai Pharma China Co., Ltd. (Roche), Clonz Biotech, Proctor & Gamble Co., Eli Lilly and Company, Enteris BioPharma, Ligand Pharmaceuticals Incorporated., Pfizer Inc., Merck Sharp & Dohme Corp. (Merck & Co., Inc.), Mylan Inc. (Viatris), Oncobiologics, Inc. and Novartis International AG.

Key Developments:

In February 2023, Sandoz received Biologics License Application (BLA) from US Food and Drug Administration (FDA) for a prospective biosimilar of denosumab (Prolia and Xgeva; Amgen). The product is intended for addressing a wide range of conditions, such as osteoporosis in postmenopausal women and in men with an elevated fracture risk, alongside numerous other medical conditions.

In July 2022, Chugai Pharma China Co., Ltd., a subsidiary of Chugai Pharmaceutical Co., Ltd. launched Edirol (eldecalcitol) in China after receiving approval from the China National Medical Products Administration (NMPA) for the treatment of postmenopausal osteoporosis. Edirol is an active vitamin D3 derivative created by Chugai.

Treatment Types Covered:

  • Bisphosphonates
  • Hormone Replacement Therapy (HRT)
  • Selective Estrogen Receptor Modulators (SERMs)
  • Monoclonal Antibodies
  • Calcium and Vitamin D Supplements
  • Anabolic Agents
  • Other Treatment Types

Route of Administrations Covered:

  • Oral
  • Parenteral
  • Transdermal
  • Nasal

Drug Delivery Systems Covered:

  • Conventional Formulations
  • Long-Acting Formulations

Patient Demographics Covered:

  • Postmenopausal Women
  • Elderly Population

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Postmenopausal Osteoporosis Treatment Market, By Treatment Type

  • 5.1 Introduction
  • 5.2 Bisphosphonates
  • 5.3 Hormone Replacement Therapy (HRT)
  • 5.4 Selective Estrogen Receptor Modulators (SERMs)
  • 5.5 Monoclonal Antibodies
  • 5.6 Calcium and Vitamin D Supplements
  • 5.7 Anabolic Agents
  • 5.8 Other Treatment Types

6 Global Postmenopausal Osteoporosis Treatment Market, By Route of Administration

  • 6.1 Introduction
  • 6.2 Oral
  • 6.3 Parenteral
    • 6.3.1 Intravenous (IV)
    • 6.3.2 Intramuscular
    • 6.3.3 Subcutaneous
  • 6.4 Transdermal
  • 6.5 Nasal

7 Global Postmenopausal Osteoporosis Treatment Market, By Drug Delivery System

  • 7.1 Introduction
  • 7.2 Conventional Formulations
  • 7.3 Long-Acting Formulations

8 Global Postmenopausal Osteoporosis Treatment Market, By Patient Demographics

  • 8.1 Introduction
  • 8.2 Postmenopausal Women
  • 8.3 Elderly Population

9 Global Postmenopausal Osteoporosis Treatment Market, By Distribution Channel

  • 9.1 Introduction
  • 9.2 Hospital Pharmacies
  • 9.3 Retail Pharmacies
  • 9.4 Online Pharmacies

10 Global Postmenopausal Osteoporosis Treatment Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 AbbVie Company (Allergan Pharmaceuticals International Ltd.)
  • 12.2 Sun Pharmaceutical Industries Ltd.
  • 12.3 Amgen Inc.
  • 12.4 BiologicsMD
  • 12.5 Chugai Pharma China Co., Ltd. (Roche)
  • 12.6 Clonz Biotech
  • 12.7 Proctor & Gamble Co.
  • 12.8 Eli Lilly and Company
  • 12.9 Enteris BioPharma
  • 12.10 Ligand Pharmaceuticals Incorporated.
  • 12.11 Pfizer Inc.
  • 12.12 Merck Sharp & Dohme Corp. (Merck & Co., Inc.)
  • 12.13 Mylan Inc. (Viatris)
  • 12.14 Oncobiologics, Inc.
  • 12.15 Novartis International AG

List of Tables

  • Table 1 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Treatment Type (2023-2034) ($MN)
  • Table 3 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Bisphosphonates (2023-2034) ($MN)
  • Table 4 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Hormone Replacement Therapy (HRT) (2023-2034) ($MN)
  • Table 5 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Selective Estrogen Receptor Modulators (SERMs) (2023-2034) ($MN)
  • Table 6 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Monoclonal Antibodies (2023-2034) ($MN)
  • Table 7 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Calcium and Vitamin D Supplements (2023-2034) ($MN)
  • Table 8 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Anabolic Agents (2023-2034) ($MN)
  • Table 9 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Other Treatment Types (2023-2034) ($MN)
  • Table 10 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Route of Administration (2023-2034) ($MN)
  • Table 11 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Oral (2023-2034) ($MN)
  • Table 12 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Parenteral (2023-2034) ($MN)
  • Table 13 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Intravenous (IV) (2023-2034) ($MN)
  • Table 14 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Intramuscular (2023-2034) ($MN)
  • Table 15 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Subcutaneous (2023-2034) ($MN)
  • Table 16 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Transdermal (2023-2034) ($MN)
  • Table 17 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Nasal (2023-2034) ($MN)
  • Table 18 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Drug Delivery System (2023-2034) ($MN)
  • Table 19 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Conventional Formulations (2023-2034) ($MN)
  • Table 20 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Long-Acting Formulations (2023-2034) ($MN)
  • Table 21 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Patient Demographics (2023-2034) ($MN)
  • Table 22 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Postmenopausal Women (2023-2034) ($MN)
  • Table 23 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Elderly Population (2023-2034) ($MN)
  • Table 24 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Distribution Channel (2023-2034) ($MN)
  • Table 25 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Hospital Pharmacies (2023-2034) ($MN)
  • Table 26 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Retail Pharmacies (2023-2034) ($MN)
  • Table 27 Global Postmenopausal Osteoporosis Treatment Market Outlook, By Online Pharmacies (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.